The current financial score of Castle Biosciences Inc is 7.31. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 103.55M, representing a year-over-year increase of 20.14%, while its net profit experienced a year-over-year increase of 145.54%.
The current valuation score of Castle Biosciences Inc is 8.05. Its current P/E ratio is -83.88, which is -285.71% below the recent high of 155.78 and -230.92% above the recent low of -277.59.
The current earnings forecast score of Castle Biosciences Inc is 9.11. The average price target is 45.11, with a high of 57.00 and a low of 35.00.
The current price momentum score of Castle Biosciences Inc is 3.78. Currently, the stock price is trading between the resistance level at 37.34 and the support level at 31.93, making it suitable for range-bound swing trading.
The current institutional shareholding score of Castle Biosciences Inc is 10.00. The latest institutional shareholding proportion is 91.06%, representing a quarter-over-quarter decrease of 13.92%. The largest institutional shareholder is James Simons, holding a total of 371.20K shares, representing 0.01% of shares outstanding, with 42.62% decrease in holdings.
The current risk assessment score of Castle Biosciences Inc is 6.02. The company's beta value is 1.07. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.